Is MXCT or EVH more profitable?

Evolent Health has a net margin of -26.29% compared to MaxCyte's net margin of -121.16%. Evolent Health's return on equity of 0.36% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -121.16% -20.03% -17.14% Evolent Health -26.29% 0.36% 0.10%

Which has higher earnings and valuation, ALIT or MXCT?

MaxCyte has lower revenue, but higher earnings than Alight. MaxCyte is trading at a lower price-to-earnings ratio than Alight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alight $2.26B 0.17 -$3.10B -$5.87 N/A MaxCyte $32.29M 3.98 -$44.63M -$0.37 N/A

Is ALIT or MXCT more profitable?

MaxCyte has a net margin of -121.16% compared to Alight's net margin of -137.50%. Alight's return on equity of 13.04% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Alight -137.50% 13.04% 4.42% MaxCyte -121.16% -20.03% -17.14%

Do analysts prefer MXCT or GRVY?

MaxCyte currently has a consensus price target of $5.50, suggesting a potential upside of 358.33%. Given MaxCyte's stronger consensus rating and higher possible upside, equities analysts plainly believe MaxCyte is more favorable than GRAVITY. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 GRAVITY 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, MXCT or GRVY?

GRAVITY has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than GRAVITY, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $32.29M 3.98 -$44.63M -$0.37 N/A GRAVITY $388.04M 1.12 $47.22M $7.30 8.59

Is MXCT or GRVY more profitable?

GRAVITY has a net margin of 12.63% compared to MaxCyte's net margin of -121.16%. GRAVITY's return on equity of 11.44% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -121.16% -20.03% -17.14% GRAVITY 12.63% 11.44% 9.68%

Do analysts recommend NRC or MXCT?

MaxCyte has a consensus price target of $5.50, indicating a potential upside of 358.33%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than National Research. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National Research 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 MaxCyte 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has higher valuation & earnings, NRC or MXCT?

National Research has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio National Research $137.39M 3.15 $11.60M $0.39 48.82 MaxCyte $32.29M 3.98 -$44.63M -$0.37 N/A

Which has higher earnings & valuation, IBEX or MXCT?

IBEX has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than IBEX, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IBEX $558.27M 0.72 $36.86M $3.20 9.38 MaxCyte $32.29M 3.98 -$44.63M -$0.37 N/A

Is IBEX or MXCT more profitable?

IBEX has a net margin of 7.53% compared to MaxCyte's net margin of -121.16%. IBEX's return on equity of 31.50% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets IBEX 7.53% 31.50% 16.25% MaxCyte -121.16% -20.03% -17.14%

MaxCyte (MXCT) Competitors

$1.20 -0.03 (-2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.08%)

As of 06:44 PM Eastern

Compare

MXCT vs. EVH, ALIT, GRVY, NRC, and IBEX

Should you buy MaxCyte stock or one of its competitors? MarketBeat compares MaxCyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MaxCyte include Evolent Health (EVH), Alight (ALIT), GRAVITY (GRVY), National Research (NRC), and IBEX (IBEX). These companies are all part of the "business services" industry.

How does MaxCyte compare to Evolent Health?

MaxCyte (NASDAQ:MXCT) and Evolent Health (NYSE:EVH) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

MaxCyte currently has a consensus target price of $5.50, indicating a potential upside of 358.33%. Evolent Health has a consensus target price of $6.00, indicating a potential upside of 58.52%. Given MaxCyte's higher possible upside, equities analysts plainly believe MaxCyte is more favorable than Evolent Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Evolent Health	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

MaxCyte has higher earnings, but lower revenue than Evolent Health. MaxCyte is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$32.29M	3.98	-$44.63M	-$0.37	N/A
Evolent Health	$1.89B	0.23	-$534.51M	-$4.76	N/A

68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 1.5% of Evolent Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MaxCyte has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Evolent Health has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Evolent Health has a net margin of -26.29% compared to MaxCyte's net margin of -121.16%. Evolent Health's return on equity of 0.36% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-20.03%	-17.14%
Evolent Health	-26.29%	0.36%	0.10%

In the previous week, MaxCyte had 2 more articles in the media than Evolent Health. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for Evolent Health. MaxCyte's average media sentiment score of 0.93 beat Evolent Health's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company	Overall Sentiment
MaxCyte	Positive
Evolent Health	Neutral

Summary

MaxCyte beats Evolent Health on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Alight?

Alight (NYSE:ALIT) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

96.7% of Alight shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 2.1% of Alight shares are owned by insiders. Comparatively, 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alight presently has a consensus target price of $3.56, indicating a potential upside of 390.64%. MaxCyte has a consensus target price of $5.50, indicating a potential upside of 358.33%. Given Alight's higher possible upside, equities analysts plainly believe Alight is more favorable than MaxCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alight	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

MaxCyte has a net margin of -121.16% compared to Alight's net margin of -137.50%. Alight's return on equity of 13.04% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alight	-137.50%	13.04%	4.42%
MaxCyte	-121.16%	-20.03%	-17.14%

In the previous week, Alight had 1 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for Alight and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.93 beat Alight's score of 0.78 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Alight	Positive
MaxCyte	Positive

Alight has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

MaxCyte has lower revenue, but higher earnings than Alight. MaxCyte is trading at a lower price-to-earnings ratio than Alight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alight	$2.26B	0.17	-$3.10B	-$5.87	N/A
MaxCyte	$32.29M	3.98	-$44.63M	-$0.37	N/A

Summary

Alight beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to GRAVITY?

MaxCyte (NASDAQ:MXCT) and GRAVITY (NASDAQ:GRVY) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

MaxCyte has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, GRAVITY has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

MaxCyte currently has a consensus price target of $5.50, suggesting a potential upside of 358.33%. Given MaxCyte's stronger consensus rating and higher possible upside, equities analysts plainly believe MaxCyte is more favorable than GRAVITY.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
GRAVITY	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

GRAVITY has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than GRAVITY, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$32.29M	3.98	-$44.63M	-$0.37	N/A
GRAVITY	$388.04M	1.12	$47.22M	$7.30	8.59

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 9.9% of GRAVITY shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, GRAVITY had 1 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for GRAVITY and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.93 beat GRAVITY's score of 0.62 indicating that MaxCyte is being referred to more favorably in the media.

Company	Overall Sentiment
MaxCyte	Positive
GRAVITY	Positive

GRAVITY has a net margin of 12.63% compared to MaxCyte's net margin of -121.16%. GRAVITY's return on equity of 11.44% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-20.03%	-17.14%
GRAVITY	12.63%	11.44%	9.68%

Summary

MaxCyte and GRAVITY tied by winning 8 of the 16 factors compared between the two stocks.

How does MaxCyte compare to National Research?

National Research (NASDAQ:NRC) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

MaxCyte has a consensus price target of $5.50, indicating a potential upside of 358.33%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, National Research had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for National Research and 2 mentions for MaxCyte. National Research's average media sentiment score of 1.08 beat MaxCyte's score of 0.93 indicating that National Research is being referred to more favorably in the media.

Company	Overall Sentiment
National Research	Positive
MaxCyte	Positive

National Research has a net margin of 6.52% compared to MaxCyte's net margin of -121.16%. National Research's return on equity of 122.73% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	6.52%	122.73%	14.18%
MaxCyte	-121.16%	-20.03%	-17.14%

National Research has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

47.3% of National Research shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 9.2% of National Research shares are owned by insiders. Comparatively, 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

National Research has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.15	$11.60M	$0.39	48.82
MaxCyte	$32.29M	3.98	-$44.63M	-$0.37	N/A

Summary

National Research beats MaxCyte on 10 of the 16 factors compared between the two stocks.

How does MaxCyte compare to IBEX?

IBEX (NASDAQ:IBEX) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

IBEX has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

IBEX has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than IBEX, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IBEX	$558.27M	0.72	$36.86M	$3.20	9.38
MaxCyte	$32.29M	3.98	-$44.63M	-$0.37	N/A

IBEX currently has a consensus price target of $40.00, suggesting a potential upside of 33.22%. MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 358.33%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than IBEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IBEX	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, IBEX had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for IBEX and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.93 beat IBEX's score of 0.68 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Overall Sentiment
IBEX	Positive
MaxCyte	Positive

81.2% of IBEX shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 3.4% of IBEX shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IBEX has a net margin of 7.53% compared to MaxCyte's net margin of -121.16%. IBEX's return on equity of 31.50% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IBEX	7.53%	31.50%	16.25%
MaxCyte	-121.16%	-20.03%	-17.14%

Summary

IBEX beats MaxCyte on 9 of the 16 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$128.55M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-3.24	17.93	22.30	24.19
Price / Sales	3.98	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	0.75	6.63	9.84	6.72
Net Income	-$44.63M	$24.20M	$3.57B	$337.19M
7 Day Performance	11.11%	-3.24%	-1.16%	0.48%
1 Month Performance	36.36%	0.53%	3.85%	5.07%
1 Year Performance	-47.37%	47.24%	27.40%	34.25%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
MXCT MaxCyte	3.8684 of 5 stars	$1.20 -2.4%	$5.50 +358.3%	-45.6%	$128.55M	$32.29M	N/A	80
EVH Evolent Health	2.2621 of 5 stars	$3.83 -3.0%	$6.00 +56.7%	-47.7%	$444.30M	$1.88B	N/A	4,200
ALIT Alight	3.968 of 5 stars	$0.88 +7.6%	$3.56 +304.2%	-84.3%	$437.22M	$2.26B	1.90	9,500
GRVY GRAVITY	1.1641 of 5 stars	$63.09 +1.0%	N/A	+0.7%	$434.17M	$388.04M	8.56	340
NRC National Research	1.0193 of 5 stars	$19.04 -0.2%	N/A	+42.2%	$434M	$137.39M	21.68	490

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. EVH, ALIT, GRVY, NRC, and IBEX

How does MaxCyte compare to Evolent Health?

Summary

How does MaxCyte compare to Alight?

Summary

How does MaxCyte compare to GRAVITY?

Summary

How does MaxCyte compare to National Research?

Summary

How does MaxCyte compare to IBEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. EVH, ALIT, GRVY, NRC, and IBEX

How does MaxCyte compare to Evolent Health?

Do analysts recommend MXCT or EVH?

Which has stronger earnings & valuation, MXCT or EVH?

Do insiders & institutionals believe in MXCT or EVH?

Which has more risk & volatility, MXCT or EVH?

Is MXCT or EVH more profitable?

Does the media refer more to MXCT or EVH?

Summary

How does MaxCyte compare to Alight?

Do insiders & institutionals have more ownership in ALIT or MXCT?

Do analysts prefer ALIT or MXCT?

Is ALIT or MXCT more profitable?

Does the media prefer ALIT or MXCT?

Which has more volatility and risk, ALIT or MXCT?

Which has higher earnings and valuation, ALIT or MXCT?

Summary

How does MaxCyte compare to GRAVITY?

Which has more risk and volatility, MXCT or GRVY?

Do analysts prefer MXCT or GRVY?

Which has preferable earnings and valuation, MXCT or GRVY?

Do insiders & institutionals hold more shares of MXCT or GRVY?

Does the media refer more to MXCT or GRVY?

Is MXCT or GRVY more profitable?

Summary

How does MaxCyte compare to National Research?

Do analysts recommend NRC or MXCT?

Does the media favor NRC or MXCT?

Is NRC or MXCT more profitable?

Which has more risk & volatility, NRC or MXCT?

Do insiders & institutionals believe in NRC or MXCT?

Which has higher valuation & earnings, NRC or MXCT?

Summary

How does MaxCyte compare to IBEX?

Which has more risk and volatility, IBEX or MXCT?

Which has higher earnings & valuation, IBEX or MXCT?

Do analysts prefer IBEX or MXCT?

Does the media refer more to IBEX or MXCT?

Do institutionals & insiders have more ownership in IBEX or MXCT?

Is IBEX or MXCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools